UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032875
Receipt number R000037487
Scientific Title Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma
Date of disclosure of the study information 2018/07/01
Last modified on 2021/06/07 09:51:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma

Acronym

Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma

Scientific Title

Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma

Scientific Title:Acronym

Feasibility study of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma

Region

Japan


Condition

Condition

metastatic lung tumors from adenoid cystic carcinoma

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety of radiotherapy using CyberKnife for metastatic lung tumors from adenoid cystic carcinoma

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Toxicity

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

12 years-old <=

Age-upper limit

95 years-old >=

Gender

Male and Female

Key inclusion criteria

1) diagnosed as metastatic lung tumors from adenoid cystic carcinoma in clinical course
2) measurable tumors
3) a performance status of 0-2

Key exclusion criteria

The presence of other primary cancers

Target sample size

5


Research contact person

Name of lead principal investigator

1st name Tsuneo
Middle name
Last name Shimizu

Organization

Kanto Neurosurgical Hospital

Division name

Cyber Center

Zip code

360-0804

Address

1120, Dai, Kumagaya, Saitama 360-0804 JAPAN

TEL

048-521-3133

Email

kantou@ps.ksky.ne.jp


Public contact

Name of contact person

1st name Hiro
Middle name
Last name Sato

Organization

Gunma University Graduate School of Medicine

Division name

Department of Radiation Oncology

Zip code

371-8511

Address

3-39-22 Showa-machi, Maebashi, Gunma 371-8511 JAPAN

TEL

027-220-8383

Homepage URL


Email

h-sato0808@hotmail.co.jp


Sponsor or person

Institute

Kanto Neurosurgical Hospital

Institute

Department

Personal name



Funding Source

Organization

Kanto Neurosurgical Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kanto Neurosurgical Hospital

Address

1120, Dai, Kumagaya, Saitama 360-0804 JAPAN

Tel

048-521-3133

Email

kantou@ps.ksky.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 07 Month 01 Day


Related information

URL releasing protocol

https://pubmed.ncbi.nlm.nih.gov/33838695/

Publication of results

Partially published


Result

URL related to results and publications

https://pubmed.ncbi.nlm.nih.gov/33838695/

Number of participants that the trial has enrolled

1

Results

The patient underwent SBRT at 60 Gy in 10 sequential fractions for each tumor. The biologically effective dose based on an alpha/beta ratio of 2 Gy was 240 Gy per tumor. The percentage of the total lung volume irradiated with >20 Gy was 4.9%, 3.2%, and 2.6% for each tumor.

Results date posted

2021 Year 06 Month 07 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

A 76-year-old Japanese man with ACC who was treated with carbon ion radiotherapy for a primary oropharynx tumor presented with three metastatic lesions in the lung.

Participant flow

The total dose was 64 Gy (relative biological effectiveness) delivered in 16 fractions. After 30 months, there was no recurrence of the primary lesion; however, the metastatic lung tumors had increased in size.

Adverse events

The patient developed acute radiation pneumonitis during the initial therapy, which resolved at 6 months after the CyberKnife treatment. At 21 months after the first CyberKnife treatment, three tumors showed no signs of recurrence. No late toxicity was observed.

Outcome measures

The patient underwent SBRT at 60 Gy in 10 sequential fractions for each tumor. The biologically effective dose based on an alpha/beta ratio of 2 Gy was 240 Gy per tumor. The percentage of the total lung volume irradiated with >20 Gy was 4.9%, 3.2%, and 2.6% for each tumor.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2018 Year 06 Month 05 Day

Date of IRB

2018 Year 06 Month 05 Day

Anticipated trial start date

2018 Year 06 Month 07 Day

Last follow-up date

2019 Year 12 Month 25 Day

Date of closure to data entry

2019 Year 12 Month 25 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

1) diagnosed as metastatic lung tumors from adenoid cystic carcinoma in clinical course
2) measurable tumors
3) a performance status of 0-2


Management information

Registered date

2018 Year 06 Month 05 Day

Last modified on

2021 Year 06 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037487


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name